The Biochemistry and Biotechnology Facility (BBF) makes available to Fox Chase Cancer Center (FCCC) investigators a group of state-of-the-art technologies for the identification, characterization, and utilization of genes, polymorphisms, transcripts, proteins;and peptides. The four components of BBF are all important and synergistic. DMA Synthesis delivers error-free oligonucleotides, regular, modified, or fluorescent probes, overnight with full quality control, Quantitative Real-time PCR provides high sensitivity and accuracy gene expression quantitation and distinguishes regulation by alternate transcripts. Mass Spectrometry identifies the components of protein complexes and supports biochemical, biophysical, and drug research. Proteomics reveals the global protein changes and modifications in response to disease states or drug treatments and discovers secondary targets of cancer-causing mutations. Anthony T. Yeung, Ph.D., (Biomolecular Structure and Function) directs BBF to provide uniformly high quality products at the cutting edge of performance. This is accomplished by proactive user interactions, and external collaborations with the leaders in each discipline. The Facility is used by 53 peer-reviewed investigators with 130 grants involving all three FCCC Divisions. About 95% of its use is by investigators with peer-reviewed funding. During the last grant period, demands on DNA synthesis (700 oligonucleotides per month by 2003) and Mass Spectrometry (about 22 projects in 2003) have both doubled. In addition, new services of Quantitative Real-time PCR and Proteomics have been developed in BBF because they are critical technologies for cancer research and are used by 13 and 7 investigators, respectively. In 2003, DNA Synthesis has contributed to 48 peer-reviewed, funded investigators, Quantitative Real-time PCR, 14;Mass Spectrometry, 23;and Proteomics, 7. BBF personnel have in-depth understanding of the science of the users and facilitate their research as highly integrated tools and participants of these research programs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006927-47
Application #
7881777
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2009-07-01
Budget End
2010-06-30
Support Year
47
Fiscal Year
2009
Total Cost
$586,248
Indirect Cost
Name
Fox Chase Cancer Center
Department
Type
DUNS #
073724262
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Bai, Tian; Chanda, Ashis Kumar; Egleston, Brian L et al. (2018) EHR phenotyping via jointly embedding medical concepts and words into a unified vector space. BMC Med Inform Decis Mak 18:123
Mehrazin, Reza; Dulaimi, Essel; Uzzo, Robert G et al. (2018) The correlation between gain of chromosome 8q and survival in patients with clear and papillary renal cell carcinoma. Ther Adv Urol 10:3-10
Tang, Baiqing; Lee, Hyung-Ok; An, Serim S et al. (2018) Specific Targeting of MTAP-Deleted Tumors with a Combination of 2'-Fluoroadenine and 5'-Methylthioadenosine. Cancer Res 78:4386-4395
Fang, Carolyn Y; Tseng, Marilyn (2018) Ethnic density and cancer: A review of the evidence. Cancer 124:1877-1903
Malik, R; Luong, T; Cao, X et al. (2018) Rigidity controls human desmoplastic matrix anisotropy to enable pancreatic cancer cell spread via extracellular signal-regulated kinase 2. Matrix Biol :
Giri, Veda N; Obeid, Elias; Hegarty, Sarah E et al. (2018) Understanding of multigene test results among males undergoing germline testing for inherited prostate cancer: Implications for genetic counseling. Prostate 78:879-888
Anari, Fern; O'Neill, John; Choi, Woonyoung et al. (2018) Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-invasive Bladder Cancer: Results of a Phase 2 Trial. Eur Urol Oncol 1:54-60
Drilon, Alexander; Laetsch, Theodore W; Kummar, Shivaani et al. (2018) Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med 378:731-739
Nacson, Joseph; Krais, John J; Bernhardy, Andrea J et al. (2018) BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance. Cell Rep 25:1384
Nikonova, Anna S; Deneka, Alexander Y; Kiseleva, Anna A et al. (2018) Ganetespib limits ciliation and cystogenesis in autosomal-dominant polycystic kidney disease (ADPKD). FASEB J 32:2735-2746

Showing the most recent 10 out of 1280 publications